LICENSING REQUIREMENTS FOR BIOTECHNOLOGY FACILITIES

1. INTRODUCTION

Biotechnology facilities conduct activities ranging from basic biological research and microbial cultivation to genetic engineering, vaccine production, pharmaceutical manufacturing, and clinical testing. Because these activities may involve hazardous microorganisms, genetically engineered organisms, human biological materials, and environmental risks, their establishment and operation are governed by multiple legal and regulatory requirements.

In India, there is no single licence covering every biotechnology facility. The applicable approvals depend on the facility's activities, organisms handled, products manufactured, containment level, and environmental impact. Operating without a required approval may result in regulatory restrictions, prosecution, closure, or other statutory consequences.

2. PRINCIPAL LICENSING AND APPROVAL REQUIREMENTS

A. Biosafety approvals

The Environment (Protection) Act, 1986, and the Manufacture, Use, Import, Export and Storage of Hazardous Microorganisms/Genetically Engineered Organisms or Cells Rules, 1989, establish the principal framework for regulated biological activities.

The Institutional Biosafety Committee (IBSC) supervises relevant institutional research activities. The Review Committee on Genetic Manipulation (RCGM) oversees specified research and development activities, while the Genetic Engineering Appraisal Committee (GEAC) performs regulatory and approval functions for activities within its jurisdiction. Applicable permissions depend on the proposed work; not every biotechnology laboratory requires every committee's approval.

B. Laboratory containment certification

Facilities handling high-risk microorganisms may need to satisfy applicable biosafety containment requirements. The National Guidelines for the Establishment and Certification of Biosafety Level-3 (BSL-3) Containment Facility, 2024, superseded the 2020 guidelines and establish certification arrangements for covered BSL-3 facilities.

C. Pharmaceutical and biological manufacturing

Facilities manufacturing regulated drugs, vaccines, recombinant-DNA products, or cell-based products must obtain applicable manufacturing licences and regulatory permissions under the Drugs and Cosmetics Act, 1940, the Drugs Rules, 1945, and other applicable requirements. Clinical trials and marketing authorisation may require separate approvals from the Central Drugs Standard Control Organisation (CDSCO).

D. Environmental and waste-management permissions

Depending on the activities, facilities may require consent to establish and consent to operate under applicable pollution-control legislation. Additional permissions may apply to hazardous waste, biomedical waste, air emissions, wastewater discharge, building use, and fire safety.

3. RELEVANT CASE LAWS

1. Vellore Citizens' Welfare Forum v. Union of India (1996) — Direct authority on environmental compliance

The Supreme Court recognised the precautionary principle and polluter-pays principle as part of Indian environmental law. These principles support preventive safeguards and remediation where biotechnology operations create environmental risks or cause pollution.

2. Indian Council for Enviro-Legal Action v. Union of India (1996) — Direct authority on environmental liability

The Supreme Court held polluting industries responsible for the costs of remedying environmental damage. The case is relevant where a biotechnology facility's unlawful discharge or waste-management failures cause environmental harm.

3. A.P. Pollution Control Board v. Prof. M.V. Nayudu (1999) — Direct authority on scientific risk assessment

The Supreme Court examined environmental decision-making under conditions of scientific uncertainty and emphasised the importance of expertise and precaution. Its reasoning is relevant to the assessment of biosafety risks before authorising potentially hazardous biotechnology activities.

4. M.C. Mehta v. Union of India (Oleum Gas Leak Case) (1987) — Direct authority on hazardous-activity liability

The Supreme Court established the principle of absolute liability for enterprises engaged in hazardous or inherently dangerous activities. Where the relevant legal conditions are met, a biotechnology enterprise conducting such activities may face stringent liability for resulting harm.

5. Narmada Bachao Andolan v. Union of India (2000) — Analogous authority on regulatory clearance

The Supreme Court considered environmental clearance and development-related decision-making in the context of a major infrastructure project. The judgment illustrates the importance of evaluating statutory approvals and environmental safeguards, although it does not specifically concern biotechnology licensing.

6. Aruna Rodrigues v. Union of India (2024) — Direct authority on biotechnology regulatory governance

In litigation concerning genetically modified mustard, the Supreme Court delivered separate opinions addressing regulatory oversight and environmental concerns associated with genetically modified crops. The divided decision highlights continuing legal scrutiny of biotechnology approvals and biosafety assessment. Its precise precedential effect must be assessed in light of the separate opinions and subsequent proceedings; it should not be treated as establishing a universal licensing rule for every biotechnology facility.

4. PRACTICAL COMPLIANCE REQUIREMENTS

Before commencing operations, a biotechnology facility should:

Classify its activities, biological materials, and applicable containment requirements.

Establish and register an IBSC where required.

Obtain applicable biosafety, environmental, manufacturing, and clinical-research approvals.

Maintain validated equipment, staff training records, waste-management procedures, and emergency response plans.

Preserve inspection records, incident reports, and regulatory correspondence.

Renew licences and report material changes where required by the relevant authority.

Approvals are activity-specific. A licence for pharmaceutical manufacturing does not automatically authorise environmental release of a genetically engineered organism, and biosafety approval does not replace a required drug-manufacturing licence.

5. CONCLUSION

Biotechnology facility licensing in India involves coordinated compliance with biosafety, environmental, pharmaceutical, and workplace requirements. The applicable approvals must be identified before construction, research, manufacture, or operation begins. Judicial decisions concerning environmental protection, scientific uncertainty, and hazardous activities reinforce the importance of preventive safeguards and regulatory accountability. A facility should maintain a documented approval register, review changes in its activities, and ensure that all required permissions remain valid throughout its operations.